Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|CT16||EGFR Antibody 29 NOTCH2 Antibody 3 NOTCH3 Antibody 2||CT16 is an antibody that targets both EGFR and NOTCH2/3, resulting in decreased ligand binding and downstream signaling, and potentially leading to decreased tumor growth and increased sensitivity to radiotherapy (PMID: 28275151).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||lung cancer||not applicable||CT16||Preclinical - Pdx||Actionable||In a preclinical study, CT16 treatment decreased NOTCH and EGFR signaling and inhibited tumor growth in lung cancer patient-derived xenograft (PDX) models sensitive to EGFR blockade (PMID: 28275151).||28275151|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|